ICON and Pfizer Honoured as Clinical Research Team of the Year at the Clinical and Research Excellence Awards
16 Mai 2016 - 11:55AM
Business Wire
Joint ICON and Pfizer team win award for
excellence in study start-up and patient recruitment in
cardiovascular outcome studies
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that,
together with Pfizer, it has won the Clinical Research Team of the
Year award at the inaugural Clinical and Research Excellence (CARE)
Awards which took place in Boston on the 27th April.
The award honoured the achievements of the team that has made
the most difference to a pharmaceutical or biotechnology company’s
research program, and has made great strides on its core project
through exemplary team-working.
ICON and Pfizer won the award for their achievements in 2015 on
two ongoing parallel cardiovascular outcome studies, which will
involve approximately 26,000 patients at 3,000 sites in 35
countries. Through close collaboration and by adopting a single
team approach, ICON and Pfizer designed a framework that
re-engineered the site start-up process and enabled them to meet or
exceed the studies’ site activation and patient enrolment targets
for 2015.
Pfizer has created SPIRE (Studies of PCSK9 Inhibition and the
Reduction of vascular Events), an extensive research program to
study bococizumab, its investigational Proprotein Convertase
Subtilisin Kexin type 9 inhibitor (PCSK9i). The SPIRE Phase 3
global clinical development program consists of six lipid-lowering
studies (SPIRE-SI, SPIRE-AI, SPIRE-HR, SPIRE-FH, SPIRE-LL and
SPIRE-LDL) as well as two cardiovascular outcome studies (SPIRE-1
and SPIRE-2).
The two cardiovascular outcome studies are investigating the
ability of bococizumab to reduce the risk of cardiovascular events
in a broad range of high-risk primary and secondary prevention
patients, including those with diabetes, chronic kidney disease,
peripheral vascular disease or familial hypercholesterolemia, in
addition to those with previous cardiovascular events such as heart
attack, stroke, or cardiovascular revascularization procedures.
Commenting on the award, ICON’s Chief Executive, Ciaran Murray,
said: “We are proud that the expertise of our clinical research
teams and our partnership approach with clients have been
recognised as the industry’s best. Site activation and patient
recruitment are two of the most challenging aspects of managing
clinical studies and it was particularly pleasing that all
timelines in these studies were either met or exceeded, thanks to
the hard work of the combined Pfizer and ICON team. Building strong
teams that have the knowledge and experience to act as trusted
partners to our clients is a key focus at ICON and I’m delighted
that one of our teams has been honoured by the industry.”
Commenting on the award, Pfizer’s Vice President for Clinical
Operations, Bill Erhardt said “The SPIRE program for bococizumab is
the only PCSK9i research program assessing cardiovascular outcomes
in a broad range of high-risk primary and secondary prevention
patients. It is only through a close partnership, innovative
problem solving and teamwork that landmark trials of this magnitude
can be completed efficiently in order to completely characterize
this important potential new medicine. Pfizer is very pleased that
this team has been recognized with the CARE award.”
Bococizumab is an investigational compound and has not received
regulatory approval in any country.
The inaugural CARE Awards celebrate the outstanding clinical
research achievements from 2015. The awards showcase excellence in
clinical trial design, technological advancements within the
industry, outstanding research results, as well as achievements of
individuals, departments, teams, or organizations. Award winners
have contributed to the advancement of therapies for unmet medical
needs, undertaken ground-breaking collaborations, and contributed
to positive clinical outcomes while demonstrating best practices
and innovation. More detail on the CARE awards and the 2016 winners
is at https://ibiawards.com/careawards/.
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 89 locations in 37 countries and has approximately
12,200 employees.
Further information is available at www.iconplc.com
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160516005656/en/
ICON Media ContactCamille FrederixWeber Shandwick+44 (0)
207 067 0272cfrederix@webershandwick.com
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024